PTHS

SEC Filing Summary: Channel Therapeutics Corporation (CHRO)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. The registrant is Channel Therapeutics Corporation, a clinical-stage biotechnology company focused on developing NaV1.7 blockers for pain management. The company is an emerging growth company and a smaller reporting company. As of May 13, 2025, there were 6,595,850 shares of common stock outstanding. The company recently entered into a merger agreement to acquire LNHC, Inc., with the combined entity expected to be renamed Pelthos Therapeutics Inc.

Key Financial Metrics

Material Changes vs. Prior Period

• Liquidity Decline: Cash balances decreased by approximately $382,000 during the quarter, dropping from $513,443 at year-end 2024 to $131,317 at March 31, 2025. This represents a significant reduction in the company's runway.
• Expense Reduction: Total operating expenses decreased by 5% to $1.83 million, driven primarily by a 58% reduction in Research and Development (R&D) expenses ($194k vs. $467k) due to lower Chemistry, Manufacturing, and Controls (CMC) fees. However, General and Administrative (G&A) expenses increased by 38% to $1.09 million due to higher compensation and stock-based compensation.
• Debt Position: The company issued a new $325,000 bridge note in February 2025. Several existing notes, including a May 2024 promissory note and a related-party note, are currently in default, though no formal notices of default have been received from holders.
• Interest Expense: Other expenses decreased by 79% to $134k, largely due to the acceleration of debt discount amortization in Q1 2024 upon the IPO conversion of notes.

Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next twelve months. The company has a working capital deficit of $4.2 million and cash of only $0.1 million. It expects to require additional capital to fund operations and clinical trials.
• Merger and PIPE Financing: On April 16, 2025, the company signed a merger agreement to acquire LNHC, Inc. (a Ligand Pharmaceuticals subsidiary). The transaction includes a PIPE financing of approximately $50.1 million. Upon closing, current shareholders are expected to own approximately 8.0% of the combined company. The company name will change to Pelthos Therapeutics Inc.
• Legal Proceedings: The company received a demand letter from Parexel International regarding a promissory note held by Chromocell Holdings (a related party) for approximately $682,551 plus interest. Channel Therapeutics denies liability, stating it is not a party to the note.
• Internal Controls: The company disclosed material weaknesses in internal controls, including a lack of segregation of duties and insufficient IT general controls. Disclosure controls and procedures were deemed ineffective as of March 31, 2025.
• Subsequent Debt: Following the quarter end, the company issued a new $325,000 "May Bridge Note" and extended the maturity of the February Bridge Note to September 30, 2025.

Investor Verification Checklist

• Merger Closing Conditions: Verify the status of the merger with LNHC and the closing of the $50.1 million PIPE financing, which is critical for resolving the liquidity crisis.
• Debt Default Status: Confirm whether the defaulted notes (May 2024 Promissory Note and Related Party Note) have been settled, extended, or if enforcement actions have been initiated.
• Capital Runway: Assess the sufficiency of the current cash balance ($131k) to fund operations until the merger closes or new financing is secured.
• Legal Liability: Monitor the outcome of the Parexel demand letter to ensure no unexpected liabilities are assumed by the company.
• Internal Control Remediation: Review the company's plan to address the material weaknesses in financial reporting and IT controls.